hydrochloric acid has been researched along with Barrett Epithelium in 21 studies
Hydrochloric Acid: A strong corrosive acid that is commonly used as a laboratory reagent. It is formed by dissolving hydrogen chloride in water. GASTRIC ACID is the hydrochloric acid component of GASTRIC JUICE.
hydrogen chloride : A mononuclear parent hydride consisting of covalently bonded hydrogen and chlorine atoms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gastroesophageal reflux disease (GERD) clinically predisposes to columnar Barrett's metaplasia (BM) in the distal esophagus." | 1.46 | Barrett's metaplasia develops from cellular reprograming of esophageal squamous epithelium due to gastroesophageal reflux. ( Bajpai, M; Cheng, CL; Chouthai, AA; Das, KM; Geng, X; Minacapelli, CD; Souza, R; Spechler, SJ, 2017) |
| "Twenty-three patients with Barrett's esophagus and 12 healthy controls were examined." | 1.46 | Patients with Barrett's esophagus are hypersensitive to acid but hyposensitive to other stimuli compared with healthy controls. ( Drewes, AM; Ejstrud, P; Gregersen, H; Krarup, AL; Lottrup, C, 2017) |
| "Patients with long segment Barrett's esophagus (LSBE) tended to have a shorter lag time than the control group, although the difference did not reach statistical significance (88 ± 54 s vs 162 ± 150 s respectively, P = 0." | 1.40 | Impairment of secondary peristalsis in Barrett's esophagus by transnasal endoscopy-based testing. ( Arakawa, H; Kaise, M; Kobayashi, G; Tajiri, H, 2014) |
| "Eosinophilic esophagitis mimics GERD, but eosinophil granule proteins, known to mediate inflammation, have not been linked to BE." | 1.36 | Inflammatory mediators of esophagitis alter p27 Kip1 expression in esophageal epithelial cells. ( Blain, SW; Gress, F; Nguyen, KD; Treem, WR, 2010) |
| "During endoscopy in patients with GERD with and without Barrett's esophagus, we took biopsy specimens from the distal squamous esophagus to study MAPK proteins before and after esophageal perfusion with 0." | 1.35 | Differences in activity and phosphorylation of MAPK enzymes in esophageal squamous cells of GERD patients with and without Barrett's esophagus. ( Chen, X; Elder, F; Hormi-Carver, K; Souza, RF; Spechler, SJ; Thomas, D; Zhang, HY; Zhang, X, 2008) |
| "During endoscopy in patients with Barrett's esophagus, we took biopsy specimens from the metaplastic mucosa before and after esophageal perfusion with 0." | 1.35 | In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks. ( Hormi-Carver, K; Souza, RF; Spechler, SJ; Zhang, HY; Zhang, X, 2009) |
| "For patients with Barrett's esophagus, physicians commonly prescribe antisecretory medications in dosages above those required to heal reflux esophagitis because acid has been shown to have proproliferative and antiapoptotic effects on Barrett's cancer cells and on Barrett's mucosal explants." | 1.34 | Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. ( Feagins, LA; Hormi-Carver, K; Quinones, MH; Ramirez, RD; Souza, RF; Spechler, SJ; Terada, LS; Thomas, D; Zhang, HY; Zhang, X, 2007) |
| "Patients with Barrett's esophagus have demonstrated reduced chemo- and mechanoreceptor sensitivity to acid infusion and balloon distension, respectively." | 1.30 | Reduced chemoreceptor sensitivity in patients with Barrett's esophagus may be related to age and not to the presence of Barrett's epithelium. ( Fass, R; Garewal, H; Grade, A; Johnson, C; Pulliam, G; Sampliner, RE, 1997) |
| "Patients with Barrett's esophagus had sensitivity to esophageal acid perfusion less frequently than those with uncomplicated reflux esophagitis (66 vs." | 1.27 | Esophageal acid sensitivity in Barrett's esophagus. ( Cattau, EL; Chobanian, SJ; Johnson, DA; Spurling, TJ; Winters, C, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.76) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 8 (38.10) | 29.6817 |
| 2010's | 9 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Minacapelli, CD | 1 |
| Bajpai, M | 3 |
| Geng, X | 2 |
| Cheng, CL | 1 |
| Chouthai, AA | 1 |
| Souza, R | 1 |
| Spechler, SJ | 5 |
| Das, KM | 3 |
| Kessel, R | 1 |
| Bhagat, T | 1 |
| Nischal, S | 1 |
| Yu, Y | 1 |
| Verma, A | 1 |
| Kobayashi, G | 1 |
| Kaise, M | 1 |
| Arakawa, H | 1 |
| Tajiri, H | 1 |
| Lottrup, C | 1 |
| Krarup, AL | 1 |
| Gregersen, H | 1 |
| Ejstrud, P | 1 |
| Drewes, AM | 1 |
| Zhang, HY | 3 |
| Zhang, X | 3 |
| Chen, X | 1 |
| Thomas, D | 2 |
| Hormi-Carver, K | 3 |
| Elder, F | 1 |
| Souza, RF | 4 |
| Kong, Y | 1 |
| Kulkarni, D | 1 |
| Mishra, P | 1 |
| Banerjee, D | 1 |
| Hirshfield, K | 1 |
| Nguyen, KD | 1 |
| Blain, SW | 1 |
| Gress, F | 1 |
| Treem, WR | 1 |
| Goldman, A | 1 |
| Shahidullah, M | 1 |
| Goldman, D | 1 |
| Khailova, L | 1 |
| Watts, G | 1 |
| Delamere, N | 1 |
| Dvorak, K | 1 |
| Hong, J | 1 |
| Resnick, M | 1 |
| Behar, J | 1 |
| Wands, J | 1 |
| DeLellis, RA | 1 |
| Cao, W | 1 |
| Kosoff, RE | 1 |
| Gardiner, KL | 1 |
| Merlo, LM | 1 |
| Pavlov, K | 1 |
| Rustgi, AK | 1 |
| Maley, CC | 1 |
| Fitzgerald, RC | 2 |
| Abdalla, S | 1 |
| Onwuegbusi, BA | 1 |
| Sirieix, P | 2 |
| Saeed, IT | 1 |
| Burnham, WR | 1 |
| Farthing, MJ | 1 |
| Marchetti, M | 1 |
| Caliot, E | 1 |
| Pringault, E | 1 |
| Fletcher, J | 1 |
| Gillen, D | 1 |
| Wirz, A | 1 |
| McColl, KE | 1 |
| Morgan, C | 1 |
| Alazawi, W | 1 |
| Freeman, T | 1 |
| Coleman, N | 1 |
| Fitzgerald, R | 1 |
| Feagins, LA | 1 |
| Quinones, MH | 1 |
| Terada, LS | 2 |
| Ramirez, RD | 1 |
| Omary, MB | 1 |
| Triadafilopoulos, G | 1 |
| Fass, R | 2 |
| Yalam, JM | 1 |
| Camargo, L | 1 |
| Johnson, C | 2 |
| Garewal, HS | 1 |
| Sampliner, RE | 2 |
| Grade, A | 1 |
| Pulliam, G | 1 |
| Garewal, H | 1 |
| Shewmake, K | 1 |
| Johnson, DA | 1 |
| Winters, C | 1 |
| Spurling, TJ | 1 |
| Chobanian, SJ | 1 |
| Cattau, EL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase IB Trial of Induction Nivolumab or Nivolumab/Relatlimab Prior to Concurrent Chemoradiation in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer[NCT03044613] | Phase 1 | 32 participants (Actual) | Interventional | 2017-07-11 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for hydrochloric acid and Barrett Epithelium
| Article | Year |
|---|---|
Barrett's esophagus evokes a quantitatively and qualitatively altered response to both acid and hypertonic solutions.
Topics: Adult; Aged; Barrett Esophagus; Double-Blind Method; Esophagus; Gastroesophageal Reflux; Humans; Hyd | 2003 |
20 other studies available for hydrochloric acid and Barrett Epithelium
| Article | Year |
|---|---|
Barrett's metaplasia develops from cellular reprograming of esophageal squamous epithelium due to gastroesophageal reflux.
Topics: Barrett Esophagus; Cell Line, Transformed; Cell Lineage; Cell Shape; Cellular Reprogramming; Epithel | 2017 |
High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in-vitro acid and bile exposure in Barrett's epithelium cells.
Topics: Barrett Esophagus; Bile; Carcinogenesis; Cells, Cultured; DNA Methylation; Epigenesis, Genetic; Gast | 2013 |
Impairment of secondary peristalsis in Barrett's esophagus by transnasal endoscopy-based testing.
Topics: Adult; Barrett Esophagus; Case-Control Studies; Endoscopy; Esophageal Motility Disorders; Esophagus; | 2014 |
Patients with Barrett's esophagus are hypersensitive to acid but hyposensitive to other stimuli compared with healthy controls.
Topics: Adult; Aged; Barrett Esophagus; Electric Stimulation; Esophagus; Female; Gastroesophageal Reflux; Ho | 2017 |
Differences in activity and phosphorylation of MAPK enzymes in esophageal squamous cells of GERD patients with and without Barrett's esophagus.
Topics: Barrett Esophagus; Cell Line, Transformed; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21 | 2008 |
In benign Barrett's epithelial cells, acid exposure generates reactive oxygen species that cause DNA double-strand breaks.
Topics: 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Acetylcysteine; Barrett Esophagus; Biopsy; Cell Li | 2009 |
Transformation of benign Barrett's epithelium by repeated acid and bile exposure over 65 weeks: a novel in vitro model.
Topics: Animals; Barrett Esophagus; Bile; Cell Line; Cell Proliferation; Cell Transformation, Neoplastic; Cy | 2011 |
Inflammatory mediators of esophagitis alter p27 Kip1 expression in esophageal epithelial cells.
Topics: Barrett Esophagus; Biological Transport; Biomarkers; Cell Line; Cell Nucleus; Cell Proliferation; Ch | 2010 |
A novel mechanism of acid and bile acid-induced DNA damage involving Na+/H+ exchanger: implication for Barrett's oesophagus.
Topics: Barrett Esophagus; Bile Acids and Salts; Cation Transport Proteins; Cell Line; DNA Damage; Dose-Resp | 2010 |
Role of Rac1 in regulation of NOX5-S function in Barrett's esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Analysis of Variance; Barrett Esophagus; Cell Line, Tumor; Cytosol; Endoplasmic Reti | 2011 |
Development and characterization of an organotypic model of Barrett's esophagus.
Topics: Barrett Esophagus; Cell Line, Transformed; Coculture Techniques; Collagen; Epithelial Cells; Esophag | 2012 |
Inflammatory gradient in Barrett's oesophagus: implications for disease complications.
Topics: Adenocarcinoma; Adult; Aged; Barrett Esophagus; Bile Acids and Salts; Cells, Cultured; Esophageal Ne | 2002 |
Chronic acid exposure leads to activation of the cdx2 intestinal homeobox gene in a long-term culture of mouse esophageal keratinocytes.
Topics: Adult; Animals; Barrett Esophagus; Caco-2 Cells; CDX2 Transcription Factor; Cell Differentiation; Ce | 2003 |
In vitro acid exposure has a differential effect on apoptotic and proliferative pathways in a Barrett's adenocarcinoma cell line.
Topics: Adenocarcinoma; Apoptosis; Barrett Esophagus; Caspase 3; Caspases; Cell Cycle; Cell Division; Cell L | 2004 |
Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells.
Topics: Analysis of Variance; Apoptosis; Barrett Esophagus; Blotting, Western; Cell Count; Cell Division; Ce | 2007 |
Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model.
Topics: Barrett Esophagus; Biopsy; Carrier Proteins; Cell Differentiation; Cell Division; Cell Survival; Duo | 1996 |
Increased esophageal chemoreceptor sensitivity to acid in patients after successful reversal of Barrett's esophagus.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Case-Control Studies; Chemoreceptor Cells; Combined Modality T | 1997 |
Reduced chemoreceptor sensitivity in patients with Barrett's esophagus may be related to age and not to the presence of Barrett's epithelium.
Topics: Adult; Aged; Aging; Barrett Esophagus; Chemoreceptor Cells; Epithelium; Esophagus; Follow-Up Studies | 1997 |
Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus.
Topics: Adenocarcinoma; Apoptosis; Barrett Esophagus; Biopsy; Cell Count; Cell Division; Cell Survival; Enzy | 2002 |
Esophageal acid sensitivity in Barrett's esophagus.
Topics: Adult; Aged; Barrett Esophagus; Esophageal Diseases; Esophagitis, Peptic; Esophagus; Humans; Hydroch | 1987 |